Cargando…

Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status

BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) have no curative treatment options; therefore, improving their quality of life (QOL) is an important goal. Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, is a safe oral agent that may be of benefit to a specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karim, Nagla Abdel, Musaad, Salma, Zarzour, Ahmad, Patil, Sadanand, Jazieh, Abdul Rahman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245085/ https://www.ncbi.nlm.nih.gov/pubmed/25520566 http://dx.doi.org/10.4137/CMO.S15172

Ejemplares similares

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
por: Köhne, C-H, et al.
Publicado: (2003)

Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients
por: van den Berg, Inge, et al.
Publicado: (2021)

Vascular Endothelial Growth Factor Levels in Ascites Between Chemonaive and Chemotreated Patients
por: Lee, Hae Kyung, et al.
Publicado: (2008)

Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples
por: Kuempers, Christiane, et al.
Publicado: (2021)

Histopathological Growth Pattern, Proteolysis and Angiogenesis in Chemonaive Patients Resected for Multiple Colorectal Liver Metastases
por: Eefsen, Rikke Løvendahl, et al.
Publicado: (2012)

ROS1 amplification mediates resistance to gefitinib in glioblastoma cells
por: Aljohani, Hashim, et al.
Publicado: (2015)

The first national public breast cancer screening program in Saudi Arabia
por: Abulkhair, Omalkhair A., et al.
Publicado: (2010)

The Use of Pharmacogenomics for Selection of Therapy in Non-Small-Cell Lung Cancer
por: Karim, Nagla A, et al.
Publicado: (2014)

“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion
por: Moiseyenko, Vladimir M, et al.
Publicado: (2018)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort
por: Smith, David Hersi, et al.
Publicado: (2013)

Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status
por: Wei, Zhong, et al.
Publicado: (2008)

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer
por: Veronese, M L, et al.
Publicado: (2005)

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
por: Ciardiello, F, et al.
Publicado: (2006)

High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients
por: Coebergh van den Braak, Robert R. J., et al.
Publicado: (2017)

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2016)

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
por: Kim, Young Saing, et al.
Publicado: (2016)

Future of translational research: Why go pragmatic?
por: Jazieh, Abdul Rahman
Publicado: (2011)

Letter to Editor: Implementation of Patient and Family Communication Model in Different Settings
por: Jazieh, Abdul Rahman
Publicado: (2020)

Effect of Exercise Training on Quality of Life, Symptoms, and Functional Status in Advanced-Stage Lung Cancer Patients: A Systematic Review
por: Nguyen, Tena, et al.
Publicado: (2023)

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer
por: Lee, Chung-Lin, et al.
Publicado: (2022)

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
por: He, Jian, et al.
Publicado: (2023)

The effect of marital status on stage at diagnosis and survival in Saudis diagnosed with colorectal cancer: cancer registry analysis
por: Alyabsi, Mesnad, et al.
Publicado: (2021)

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
por: Han, Ji-Youn, et al.
Publicado: (2015)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

The predictors of poor quality of life in a sample of Saudi women with breast cancer
por: Ahmed, Anwar E, et al.
Publicado: (2017)

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
por: Suzuki, R, et al.
Publicado: (2006)

Bilateral Choroidal Metastasis from Non-Small Cell Lung Cancer
por: Namad, Tariq, et al.
Publicado: (2014)

A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)
por: Stebbing, J, et al.
Publicado: (2008)

Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study
por: Xu, Yaping, et al.
Publicado: (2015)

Healthcare Transformation in the Post-Coronavirus Pandemic Era
por: Jazieh, Abdul Rahman, et al.
Publicado: (2020)

Systemic Chemotherapy for Progression of Brain Metastases in Extensive-Stage Small Cell Lung Cancer
por: Abdel Karim, Nagla, et al.
Publicado: (2015)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer
por: Xu, Jian Ming, et al.
Publicado: (2006)

Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
por: Abdel-Karim, Nagla, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aj0icgjsfoiqpba129f5r5dvq2